Immunotherapy Response Biomarkers
Predicting response to immune checkpoint inhibitors (e.g., via PD-1 glycosylation)
Key Facts
About InterVenn BioSciences
InterVenn Biosciences is a private, pre-revenue diagnostics company developing a novel liquid biopsy platform based on clinical glycoproteomics. Its core technology, GlycoVision, combines liquid chromatography-tandem mass spectrometry (LC-MS/MS) with artificial intelligence to precisely quantify intact glycopeptides, unlocking a previously untapped layer of biology for biomarker discovery. The company is building a pipeline of diagnostic applications, with early research published in high-impact journals for cancers like colorectal carcinoma, and is positioning itself as a partner for biopharma and clinicians to enable earlier disease detection and personalized treatment strategies.
View full company profile